secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005535
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3
--------------------------------------------------------------------------------

- Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
- Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.
- Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.
- Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/0001193125-26-005535-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/d28332d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005535

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer